Insmed

2 days ago · seekingalpha.com

Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Faisal Khurshid - Jefferies LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Ritu Baral - TD Cowen, Research Division Jason Zemansky - BofA Securities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Maxwell Skor - Morgan Stanley, Research Division Leonid Timashev - RBC Capital Markets, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Insmed Third Quarter 2026 Financial Results Conference Call.

3 days ago · zacks.com

Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.

3 days ago · marketbeat.com

Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.

4 days ago · zacks.com

While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

4 days ago · zacks.com

Insmed (INSM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $1.75 per share a year ago.

4 days ago · prnewswire.com

—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ®  (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026— —ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $124.4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025— —Company Raises 2026 BRINSUPRI Revenue Guidance to $1.35 Billion to $1.4 Billion— —Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million— — Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan— BRIDGEWATER, N.J., Oct. 29, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

11 days ago · zacks.com

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

13 days ago · prnewswire.com

—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately.

14 days ago · prnewswire.com

—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the commercial launch in Japan of BRINSUPRI ®  Tablets 25 mg (brensocatib hydrate), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.

18 days ago · prnewswire.com

—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of the Broadest Active Global Clinical Programs in the Pulmonary Space, With the Potential to Redefine Prostanoid Therapy for These Patient Populations— BRIDGEWATER, N.J., Oct. 15, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, will feature the global PALM Clinical Development Program at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), which is investigating treprostinil palmitil inhalation powder (TPIP) in a range of serious pulmonary diseases.